## IONS: Ionis Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.9% below STRENGTH zone (4.0-10.0%); PEG 25.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. 450,254 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Norges Bank**
- Source: MarketBeat | 20251209T110952 | Somewhat-Bullish | Relevance: 99%
-  Norges Bank recently acquired a new stake of 450,254 shares in Ionis Pharmaceuticals (NASDAQ:IONS), valued at approximately $17.79 million. This acquisition represents about 0.28% of the company, with other large institutional investors also increasing their positions. Despite notable insider stock sales totaling over $35 million in the last quarter, the company exceeded recent revenue and EPS estimates and holds a consensus analyst rating of "Moderate Buy."

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | B of A Securiti | $97 | $86 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($8.92M) |
| Sells | 20 ($5.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 14.6% (+0.2%)
- Vanguard Group Inc: 10.2% (-1.4%)
- T. Rowe Price Invest: 8.1% (-18.0%)
- Capital World Invest: 7.8% (+1.5%)
- Blackrock Inc.: 6.5% (-4.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.0% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.9M in recent transactions.
3. Valuation stretched: PEG 25.7x requires aggressive growth execution.
4. Elevated short interest (12.7%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 25.70 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (1 raises, avg +13%). Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $12.8B |
| Beta | 0.30 |
| 52W Range | $23.95 - $83.61 |
| Short Interest | 12.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 25.70 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 4.1% to -0.9% (-5.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.9pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.91% (CS: 40) | Neutral |
| RSI_14 | 56.4 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.064x | Above |
| vs SMA200 | 1.633x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $79.14
- **Stop Loss:** $74.10 (6.4% risk)
- **Target:** $84.18 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 273
- **Position Value:** $21,605.22
- **Portfolio %:** 21.61%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.05 | $-0.61 | +41.8% |
| 2025Q2 | $0.16 | $0.85 | +415.1% |
| 2025Q1 | $-1.03 | $-0.92 | +10.4% |
| 2024Q4 | $-0.84 | $-0.43 | +49.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*